Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Owen, I. Carey, S. Wilde, P. Whincup, Richard Wormald, Derek Cook (2009)
Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994–2005Eye, 23
G. Schwartz, H. Quigley (2008)
Adherence and persistence with glaucoma therapy.Survey of ophthalmology, 53 Suppl1
G. Reardon, G. Schwartz, E. Mozaffari (2003)
Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.Clinical therapeutics, 25 4
H. Quigley, A. Broman (2006)
The number of people with glaucoma worldwide in 2010 and 2020British Journal of Ophthalmology, 90
J. Spooner, M. Bullano, Laurence Ikeda, Tara Cockerham, W. Waugh, T. Johnson, E. Mozaffari (2002)
Rates of discontinuation and change of glaucoma therapy in a managed care setting.The American journal of managed care, 8 10 Suppl
R. Haynes, H. Mcdonald, A. Garg (2002)
Helping patients follow prescribed treatment: clinical applications.JAMA, 288 22
R. Fechtner, Nicholas Karunaratne, Albert Khoury, T. Realini, Jianming Ren, Michelle Robison, George Shafranov, Gilbert Sussman, Mike Willman, Thomas Uihlein, E. Hartmann, Anna Norris, Melissa Perez, M. Piccone, Anna Singh, Andrea Gray (2002)
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.Archives of ophthalmology, 120 6
J. Rouland, C. Pen, H. Benhaddi, E. Piriou, H. Lilliu, P.-A. Kenigsberg, Pascal Abellan, Michel Arnoux, Annie Attia, Christophe Baudouin, Dominique Bérard, Bertrand Boussion, Gilles Bove, Béat Cochener, Howard Cohn, Philippe Denis, Jean-Michel Filippi, Nicolas Garbolino, Christophe Gazagne, Denis Gruber, Nicolas Haaz, P. Hamard, Y. Lachkar, Claude Laroudie, Marie-Hélène Lec, Alain Grignou, Florence Malet, A. Meftah, J. Mialhe, Michel Montard, J. Nordmann, Roland Pagot, Guillaume Peigné, Jean-Paul renard, Isabelle Riss, J. Rouland, Joël Scemama, E. Sellem, Alain-David Sitruk, Xavier Subirana, Jean-Claude Timsit, W. Williamson, Serge Zaluski (2003)
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.European journal of ophthalmology, 13 Suppl 4
M. Kass, M. Gordon, R. Morley, D. Meltzer, J. Goldberg (1987)
Compliance with topical timolol treatment.American journal of ophthalmology, 103 2
J. Wilensky, R. Fiscella, A. Carlson, L. Morris, J. Walt (2006)
Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.American journal of ophthalmology, 141 1 Suppl
R. Platt, G. Reardon, E. Mozaffari (2004)
Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size.American journal of ophthalmology, 137 1 Suppl
J. Rait, M. Adena (2007)
Persistency rates for prostaglandin and other hypotensive eyedrops: population‐based study using pharmacy claims dataClinical & Experimental Ophthalmology, 35
G. Schwartz, G. Reardon, E. Mozaffari (2004)
Persistency with latanoprost or timolol in primary open-angle glaucoma suspects.American journal of ophthalmology, 137 1 Suppl
L. Feiner, J. Piltz-Seymour (2003)
Collaborative Initial Glaucoma Treatment Study: a summary of results to dateCurrent Opinion in Ophthalmology, 14
G. Reardon, G. Schwartz, E. Mozaffari (2004)
Patient persistency with topical ocular hypotensive therapy in a managed care population.American journal of ophthalmology, 137 1 Suppl
E. Vermeire, H. Hearnshaw, P. Royen, J. Denekens (2001)
Patient adherence to treatment: three decades of research. A comprehensive reviewJournal of Clinical Pharmacy and Therapeutics, 26
H. Quigley (1996)
Number of people with glaucoma worldwide.British Journal of Ophthalmology, 80
B. Nordstrom, D. Friedman, E. Mozaffari, H. Quigley, A. Walker (2005)
Persistence and adherence with topical glaucoma therapy.American journal of ophthalmology, 140 4
A. Heijl, M. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, M. Hussein (2002)
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.Archives of ophthalmology, 120 10
F. Shaya, C. Mullins, W. Wong, Jeannie Cho (2002)
Discontinuation rates of topical glaucoma medications in a managed care population.The American journal of managed care, 8 10 Suppl
M. Diestelhorst, Schaefer Cp, Beusterien Km, Plante Km, Fain Jm, E. Mozaffari, R. Dhawan (2003)
Persistency and Clinical Outcomes Associated with Latanoprost and Beta-Blocker Monotherapy: Evidence from a European Retrospective Cohort StudyEuropean Journal of Ophthalmology, 13
Samaresh Dasgupta, V. Oates, B. Bookhart, B. Vaziri, G. Schwartz, E. Mozaffari (2002)
Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.The American journal of managed care, 8 10 Suppl
Gregory Reardon, G. Schwartz, E. Mozaffari (2003)
Patient Persistency with Pharmacotherapy in the Management of GlaucomaEuropean Journal of Ophthalmology, 13
Paul Lee, J. Walt, T. Chiang, A. Guckian, J. Keener (2007)
A gap analysis approach to assess patient persistence with glaucoma medication.American journal of ophthalmology, 144 4
M. DiMatteo, Patrick Giordani, H. Lepper, T. Croghan (2002)
Patient Adherence and Medical Treatment Outcomes: A Meta-AnalysisMedical Care, 40
Z. Zhou, R. Althin, B. Sforzolini, R. Dhawan (2004)
Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United KingdomBritish Journal of Ophthalmology, 88
E. Higginbotham (2009)
Ocular Hypertension Treatment Study.Archives of ophthalmology, 127 2
G. Schwartz, R. Platt, G. Reardon, M. Mychaskiw (2007)
Accounting for restart rates in evaluating persistence with ocular hypotensives.Ophthalmology, 114 4
J. Gurwitz, S. Yeomans, R. Glynn, B. Lewis, R. Levin, J. Avorn (1998)
Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma.Medical care, 36 3
D. Day, P. Schacknow, E. Sharpe, John Ellyn, J. Kulze, A. Threlkeld, E. Jones, Reay Brown, J. Jenkins, W. Stewart (2004)
A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 20 5
SOCIOECONOMICS AND HEALTH SERVICES SECTION EDITOR: PAUL P. LEE, MD ONLINE FIRST Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population Desmond T. L. Quek, MRCSEd; Geok-Teng Ong, BSc; Shamira A. Perera, FRCOphth; Ecosse L. Lamoureux, PhD; Tin Aung, FRCOphth, PhD Objective: To determine the persistence rates of patients decreased to 11.5% (320 of 2781) after 3 years. Prosta- who started taking topical intraocular pressure (IOP)– glandin analogues had better persistence rates at 1 year lowering monotherapy in a Singapore eye hospital. compared with timolol maleate (29.6% vs 23.7%; P=.004) and all other medications combined (29.6% vs 20.6%; Methods: This was a retrospective review of patients who P.001). Those who were not persistent at year 1 were started taking a single IOP-lowering medication be- younger (P .001) and more likely to not be Sin- tween October 1, 2005, and September 30, 2006. Phar- gaporean (P=.008), not receiving government subsidies macy dispensing records were traced for 3 years from the (P.001), and receiving unilateral therapy (P.001). date of first prescription. A patient was defined as per- sistent if he or she was prescribed the same medication Conclusions: In this hospital-based study, the persis- before or within 90 days
JAMA Ophthalmology – American Medical Association
Published: May 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.